KRAS and neoplasm: KYA1797K suppresses the growth and transformation of CRC cells, reduces tumor xenograft growth and decreases the colony formation and growth of tumor organoids derived from CRC patient tissues insensitive to cetuximab due to KRAS mutations via the degradation of oncogenic KRAS and β-catenin with EGFR repression.